Completed PHASE1 INTERVENTIONAL 1-arm NCT03413319

Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104

Sponsor: AbbVie

Conditions Progressive Supranuclear Palsy (PSP)

Interventions ABBV-8E12

Updated 9 times since 2018 Last updated: Dec 2, 2019 Started: Apr 17, 2018 Primary completion: Nov 20, 2019 Completion: Nov 20, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Progressive Supranuclear Palsy (PSP) and is currently completed. AbbVie leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2020 — Jan 2021 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jan 2019 — Jan 2020 [monthly]

Active Not Recruiting PHASE1

▶ Show 4 earlier versions

Aug 2018 — Jan 2019 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Jul 2018 — Aug 2018 [monthly]

Recruiting PHASE1
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Feb 2018 — Jun 2018 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dallas, United States
• La Jolla, United States